UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.
ACHIEVE I STUDY
DEMONSTRATED RAPID RELIEF OF MIGRAINE PAIN VS. PLACEBO
2 hours after an initial dose of UBRELVY 100 mg, significantly more patients reported a reduction in headache severity from moderate or severe pain to mild pain or no pain vs. placebo.1,2†
DEMONSTRATED FREEDOM FROM MIGRAINE PAIN VS. PLACEBO
2 hours after an initial dose, 21.2% of patients receiving UBRELVY 100 mg reported migraine pain freedom vs. 11.8% of patients receiving placebo (co-primary endpoint; p=0.0001).1,2§‡
DEMONSTRATED RAPID RELIEF OF MIGRAINE PAIN VS. PLACEBO
2 hours after an initial dose of UBRELVY 100 mg, significantly more patients reported a reduction in headache severity from moderate or severe pain to mild pain or no pain vs. placebo.1,2†
DEMONSTRATED FREEDOM FROM MIGRAINE PAIN VS. PLACEBO
2 hours after an initial dose, 21.2% of patients receiving UBRELVY 100 mg reported migraine pain freedom vs. 11.8% of patients receiving placebo (co-primary endpoint; p=0.0001).1,2§‡
†Pain relief was defined as a change in the severity of headache pain from moderate or severe pain to mild pain or no pain at 2 hours after the initial dose.
‡Modified intent-to-treat (mITT) population included all randomized patients who received at least 1 dose of investigational product, recorded a baseline migraine headache severity measurement, and had ≥1 post-dose migraine headache severity measurement at or before the 2-hour timepoint.
§Freedom from pain was defined as a change in the severity of headache pain from moderate or severe pain to the presence of no pain at 2 hours after the initial dose.
References:
1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation.
2. Dodick W, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med 2019;381:2230-2241.